Replies to post #273085 on Avid Bioservices Inc (CDMO)

[entdoc]

PPHM undeniably has the attention of the "big league" players, which is critical. PPHM did not go away when it was swished. It kept on analyzing. That's where it's eat. So we have the attention of the big players, and we've had our faces pushed underwater. What's a breath of fresh air worth? We hold the keys at this point.

[Protector]

entdoc, there is a BIG difference between a statement that says that PPHM cannot/possibly cannot market a Lung Cancer treatment improvement with 2 months survival increase OR saying that such improvement cannot be marketed AT ALL (which is what MOST must have understood from your first post on the topic until in your reply below you added PPHM ability or inability by a possible lack of staff).

James GMS. Agree that + or - 2 months (or similar) of additional survival for advanced lung cancer might be a marketable product for a large pharma, but when you have zero marketing staff such as PPHM, it is doubtful.

But in reality it doesn't matter because if it is marketable by a BP then PPHM will let a BP do it if they realy cannot do that themselves (which I believe you are correct but on a MORE GENERAL level - that is PPHM cannot market ANY drug on a large scale IMO at this point in time, probably the reason why they would split the US Sales from the rest).

And by the way it is more then two months.